-
Sarepta to develop Arrowhead’s muscular dystrophy treatments
Sarepta Therapeutics is acquiring from Arrowhead Pharmaceuticals the exclusive global rights to develop ARO-DUX4 and ARO-DM1, two RNA interference (RNAi) therapeutic candidates in Phase 1/2 clinical testing, each for one type of muscular dystrophy. ARO-DUX4 is being tested for facioscapulohumeral muscular dystrophy (FSHD) and ARO-DM1 for myotonic dystrophy type 1 (DM1). Both were designed using…
-
Fashion | Dune London: Bags
With the festive season now in full swing, why not invest in something extra special from luxury retailer, Dune London. Whether looking to treat a loved one, or even yourself, I highly recommend checking out their extensive range of quality bags ~ there really is something for everyone and every occasion. (Go on, you know…
-
When the Power of Humanity Expands into the Digital Realm: “The Remarkable Life of Ibelin” Review
“The Remarkable Life of Ibelin” Review by Hawken Miller, Writer and Advocate When Mats Steen, a young Norwegian man, passed away from Duchenne muscular dystrophy at 25, his parents Robert and Trude were inconsolable. They had outlived their son, who lived what they saw as an isolated and lonely life due to the physical limitations…
